From the end of 2021 to the beginning of January 2022, the A-share traditional Chinese medicine sector continued to be hot, and ushered in the limit tide for several trading days. Behind this is the frequent emergence of traditional Chinese medicine policies at the national level, the centralized collection and landing of traditional Chinese medicine, and the prominent role of traditional Chinese medicine in the epidemic in recent years, especially since 2021. In the near future, the correction of traditional Chinese medicine sector has attracted the attention of relevant parties.
In an interview with the reporter of economic information daily, many experts said that in the medium and long term, traditional Chinese medicine will develop stably in the future. Other experts pointed out that traditional Chinese medicine enterprises should be good at using the cash flow of the traditional Chinese medicine industry to invest in drug research and development, break through the shackles and shackles of traditional Chinese medicine and other traditional industries, create a “moat” and more stimulate the endogenous development power of the industry.
policy continues to increase
At the beginning of 2022, the policy of traditional Chinese medicine continued to increase. On January 5, the State Food and Drug Administration issued a notice on publicly soliciting opinions on the guiding principles of communication and exchange technology based on the “Three Combinations” registration and evaluation evidence system (hereinafter referred to as the “guiding principles”). On the basis of the measures for the administration of drug registration and the measures for the administration of communication between drug R & D and technical review, the guiding principles further clarify the key nodes for the communication and exchange of clinical aspects of different registration classifications of new traditional Chinese medicine developed under the new evidence system for the registration and review of traditional Chinese medicine, which “combines the theory of traditional Chinese medicine, human experience and clinical trials” Meeting data requirements and concerns. The draft of the guiding principles reflects the unique law of traditional Chinese medicine, further optimizes the approval process of new traditional Chinese medicine and improves the approval efficiency. The data show that in 2021, the State Food and Drug Administration approved 12 new traditional Chinese medicine drugs, the number of which is the sum of previous years.
On the 23rd, Shandong Wohua Pharmaceutical Co.Ltd(002107) President Zeng yingzi told reporters that in recent years, the national policies on medicine, medical treatment and medical insurance have been “dizzying”. In 2021 alone, there were more than 500 policies and regulations on medicine and medical treatment. She said that as one of the important sections, traditional Chinese medicine has also received unprecedented attention and policy support.
The reporter of economic information daily learned that in 2016, the CPC Central Committee and the State Council issued the outline of the “healthy China 2030” plan, which clearly put forward that “we should pay equal attention to both traditional Chinese and Western medicine, inherit and develop the cause of traditional Chinese medicine”; On July 1, 2017, the law of the people’s Republic of China on traditional Chinese medicine was officially implemented, providing a guarantee for inheriting and carrying forward traditional Chinese medicine and promoting the development of traditional Chinese medicine; In October 25, 2019, the National Conference of Chinese medicine put forward that Chinese medicine should inherit the essence and keep innovation.
By 2021, the multiple favorable policies of traditional Chinese medicine have been gradually clarified and implemented, such as the entry of traditional Chinese medicine into the scope of centralized procurement, the strengthening of compliance and law enforcement, the expansion of basic drugs and other measures, which not only breeds new opportunities, but also brings new challenges to traditional Chinese medicine pharmaceutical enterprises.
What attracted much attention was that on December 21, 2021, the inter provincial alliance of Chinese patent medicine in 19 provinces (cities and districts) led by Hubei Province officially released the results of the proposed selection. At present, the bid opening of centralized procurement has been carried out, and the average price of the selection has decreased by 42.3%. Zeng yingzi said that the policies and implementation measures of the centralized purchase of Chinese patent medicines may become the paradigm and temsector of the centralized purchase of Chinese patent medicines in the future. The impact on the regional market pattern should not be underestimated, and then affect the competitive environment of enterprises. According to the annual report of 2021, the gingko leaf group in the cardiovascular field recorded the highest decline of 82.6% and the lowest price of 8 cents per chip. The prices of Xueshuantong and Xuesaitong injections were halved. Guangdong and Shandong also began to organize the inter provincial alliance of traditional Chinese medicine for centralized purchase, and the centralized purchase of Chinese patent medicines was fully included or will be accelerated.
On December 30, 2021, the state medical security administration and the State Administration of traditional Chinese Medicine issued the guiding opinions on medical insurance supporting the inheritance, innovation and development of traditional Chinese medicine, pointing out that medical insurance supporting the inheritance, innovation and development of traditional Chinese medicine is a specific measure to inherit, develop and make good use of traditional Chinese medicine.
With the support and promotion of a series of national policies, the role of traditional Chinese medicine has been re recognized in the covid-19 pneumonia outbreak at the beginning of 2020. In the interview, the heads of many traditional Chinese medicine enterprises believed that the performance of traditional Chinese medicine in the epidemic situation ushered in new opportunities for the development of traditional Chinese medicine industry and thickened the performance of enterprises.
In the capital market, since the end of 2021, the A-share traditional Chinese medicine sector has continued to rise. Among them, on January 4, the first trading day of 2022, Zhejiang Jolly Pharmaceutical Co.Ltd(300181) , Jiuzhitang Co.Ltd(000989) , Jinghua Pharmaceutical Group Co.Ltd(002349) , Beijing Tongrentang Co.Ltd(600085) , Zhuzhou Qianjin Pharmaceutical Co.Ltd(600479) and other stocks of more than 20 listed companies of traditional Chinese medicine set off a wave of limit trading.
traditional Chinese medicine will develop stably
Huaan Securities Co.Ltd(600909) information shows that from January 17 to 21, the pharmaceutical sub sector fell comprehensively, and the pharmaceutical biological index fell by about 7.19%. Among the pharmaceutical level III sub industries, all 13 sub industries fell, and API fell by 3.3%, with the smallest decline; Biological products fell 16.3%, the largest decline. Among them, traditional Chinese medicine fell by 7.8%, and the traditional Chinese medicine track has been deeply adjusted with the whole industry.
Hu Qimu, chief researcher of Sinosteel Economic Research Institute, said in a media interview a few days ago that for the overall traditional Chinese medicine sector, there has been a sustained and significant rise recently under the action of multiple factors such as favorable national policies and overall low valuation, but there have been signs of correction in recent trading days. At the same time, some people in the investment community also made a hint of “Beware of hot speculation of hot money”.
For traditional Chinese medicine enterprises, they are also facing the sharp rise of their raw materials. According to the 2021 annual report, since 2020, the prices of Chinese herbal raw materials, packaging materials and energy have continued to rise. In terms of traditional Chinese medicine, driven by factors such as climate, rising commodity prices and import suspension caused by the epidemic, the prices of Rehmannia glutinosa, epimedium and leech increased by more than 350%, 160% and 100% respectively in early December 2021 compared with the beginning of 2021; The prices of salt psoralen, Drynaria, peony bark, etc. also increased by a large margin.
Coo Zang Zhongtang of Gansu minhai Health Technology Co., Ltd. admitted that traditional Chinese medicine and traditional Chinese medicine have a deep social and cultural foundation and a wide audience. With the implementation of a series of national policies and the impact of the epidemic, the development of traditional Chinese medicine has continued to improve in recent years. He believes that in 2022 and the next few years, more policies will be introduced and implemented at the national level, and the recent changes in the stock market of traditional Chinese medicine and the rise in raw material prices will not affect the medium and long-term investment value of traditional Chinese medicine.
According to the data, the semi annual report of traditional Chinese medicine in 2021 has a beautiful performance. According to the data provided by Zhongtai Securities Co.Ltd(600918) Research Institute, 73 listed companies in traditional Chinese medicine achieved a total operating revenue of 162.2 billion yuan in the first half of 2021, an increase of 15.12% over the same period of last year; The total net profit attributable to shareholders of listed companies was 24.2 billion yuan, an increase of 25.05% over the same period last year; The net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was 17 billion yuan, an increase of 27.56% over the same period last year.
According to tan Guochao, chief analyst of the pharmaceutical industry of Huaan Securities Co.Ltd(600909) Research Institute, the performance release of enterprises in the traditional Chinese medicine sector is only a matter of time. The policy drive in the second half of 2021 may only be the first step and has not been completely completed. 2022 is the key year for real performance and logical realization. He said that the current is the initial stage of the development of traditional Chinese medicine industry, and he is optimistic about the opportunities of traditional Chinese medicine in the next three to five years.
In an interview with the reporter of the economic information daily, pan Helin said that the performance of the capital market, including the traditional Chinese medicine sector, will not rise all the time every day.
“In the medium and long term, traditional Chinese medicine will continue to develop steadily in the future.” Pan Helin said that however, traditional Chinese medicine enterprises should be good at using the cash flow of the traditional Chinese medicine industry to invest in drug research and development, break through the shackles and shackles of traditional Chinese medicine and other traditional industries, create a “moat” and more stimulate the endogenous development power of the industry.
